### **Overview** Bafna Pharmaceuticals Limited, headquartered in Chennai, India, is a seasoned player in the global generics and Contract Research & Manufacturing Services (CRAMS) sector with over 30 years of experience. The company specializes in **non-beta-lactam solid oral dosage forms** and has built a strong export-led business model, serving regulated markets such as the UK, EU, Australia, and emerging markets across Africa, Asia, and CIS countries. With manufacturing facilities compliant with **UK-MHRA, EU-GMP, TGA-Australia, and WHO-GMP standards**, Bafna Pharma is well-positioned to supply high-quality pharmaceutical products to stringent regulatory environments. Approximately **70% of its production is exported** to over 20 countries, underpinning its global footprint and strategic focus on international growth. --- ### **Product Portfolio & Therapeutic Focus** The company’s product portfolio spans key therapeutic areas: - **Cardiovascular**: Beta-blockers, ACE inhibitors, statins. - **Metabolic & Lifestyle Disorders**: Diabetes, hypertension. - **Oncology & Women’s Health**: Potent drugs, hormonal therapies. - **Pain Management**: Neuropathic, joint, muscular, and opioid pain. It also focuses on **differentiated dosage forms**, such as: - Modified-release tablets. - Bi-layered tablets. - Sachets. - Orally disintegrating and chewable tablets. - Pediatric-friendly formulations. Recent innovation highlights include **gastro-resistant polymer coatings**, **taste-masking technologies using ion-exchange resins**, and **multi-layer coating systems** for pH-sensitive, intestinal-release drugs — enhancing patient compliance and therapeutic efficacy. --- ### **R&D & Innovation** Bafna operates a **DSIR-approved in-house R&D center** in Chennai, focused on: - Development of **complex generics** and **novel formulations**. - **Technology transfer** and process optimization. - Regulatory dossier preparation aligned with **WHO-PQ, UK-MHRA, and EU standards**. Key R&D achievements: - **38 products successfully transferred** to regulated markets. - **50 advanced dossiers ready** for new market launches. - **8+ products in late-stage development** for the UK, Southeast Asia, and Africa. - FY2024-25 capex of **₹14 crores** invested in R&D infrastructure, including stability chambers, digital batch systems, and IP tracking. The R&D unit is evolving into an **independent profit center**, offering full-service formulation development and commercial manufacturing. **Flagship Launches:** - First-to-market **generic Prednisolone Eccentric Coated tablets** in the UK. - **Prednisolone GR tablets**, IVAB, SITAG, and RECLAP in Sri Lanka and the Philippines. --- ### **Manufacturing & Quality Infrastructure** - **State-of-the-art manufacturing facility in Chennai** certified by: - UK-MHRA - EU-GMP - TGA-Australia - WHO-GMP - Dedicated **containment area for high-potent drugs** with robust safety protocols. - **In-house Quality Control & Assurance labs** equipped with advanced instrumentation for rigorous QC. - **Flexible batch sizes** from pilot scale to commercial production. - Ongoing **brownfield expansion of Unit II**, aiming for **30% increased capacity by FY26** under the "Bafna 2.0" roadmap. --- ### **Global Commercial Operations** **Export Revenue:** >70% of total revenue, with a diversified mix across: - **Regulated Markets:** UK, Europe, Australia. - **Emerging Markets:** Africa (Nigeria, Kenya, Ethiopia, Tanzania), Sri Lanka, Philippines, Nepal. - **CIS & LATAM:** Targeted for expansion. **Market Presence:** - **Active product registrations in 20+ countries.** - **150+ products registered** in emerging markets. - **200+ products pending registration** across Africa, Asia, and other regions. - Key growth markets: **UK, Australia, Africa, South & Southeast Asia**. **Branded Generics Launched In:** - Sri Lanka, Philippines, Tanzania, Nigeria — targeting high-demand areas like **diabetes, cardiovascular diseases, and oncology**. --- ### **Market Expansion & Commercialization Strategy** **Geographic Expansion:** - **Strengthen presence in**: UK, Europe, Australia, MENA, Sri Lanka, Philippines, CIS. - **Entry into North America** planned with **advanced diabetes and oncology formulations**. - **Exploring LATAM and CIS regions** via new product filings and local partnerships. **Commercialization Initiatives:** - **Strategic alliances** with regional distributors and local manufacturing partners. - **Accelerated market access** through regulatory consultants and local compliance expertise. - Active participation in global trade events: **CPHI Worldwide, Arab Health**. - Enhanced **digital marketing and CRM systems** to boost outreach. **"Global Expansion of Complex Generics Leadership" Initiative:** Aimed at commercializing **high-value off-patent molecules** globally through innovation and regulatory excellence. --- ### **CRAMS & Contract Manufacturing** Bafna is a recognized **Contract Manufacturing Organization (CMO)** and CRAMS provider, serving global pharmaceutical leaders. - Offers **end-to-end services**: - Formulation & analytical development. - Technology transfer. - Contract manufacturing of third-party branded generics. - Supplies compliant, high-quality batches to international clients. - **35+ years of institutional relationships** with global pharma companies. The growing **global CRAMS market** (projected **$157.07B in 2025**, +9.3% YoY) supports strong demand for Bafna’s **regulatory-compliant, cost-competitive manufacturing** in India. --- ### **Financial & Operational Highlights** - **FY2023-24 Revenue**: ₹1,524.66 crores (Rs. 15,246.57 lakhs), a **32.18% YoY growth**. - **Export Mix**: ~70% of total revenue. - **Operational Focus**: Strategic sourcing, economies of scale, and quality systems to maintain **competitive pricing without compromising excellence**. --- ### **Historical Milestones & Regulatory Footprint** - **Jul 2021**: Registered in **18 countries**; 136 pending applications. - **Aug 2023**: Approvals in Ethiopia (7), Kenya (5), Honduras (4), Nepal (10); 20+ pending in Ethiopia and Nepal. - **Sep 2024**: Expanded portfolio and upgraded QC labs; ongoing focus on new registrations. - **Mar 2020**: Shift from litigation recovery to bottom-line optimization; focus on R&D and specialty generics.